



Direct and indirect healthcare costs of lung cancer CT screening in Denmark a registry study

Jensen, Manja Dahl; Siersma, Volkert Dirk; Rasmussen, Jakob Fraes; Brodersen, John

Published in:
B M J Open

DOI:
[10.1136/bmjopen-2019-031768](https://doi.org/10.1136/bmjopen-2019-031768)

Publication date:
2020

Document version
Publisher's PDF, also known as Version of record

Document license:
[CC BY-NC](https://creativecommons.org/licenses/by-nc/4.0/)

Citation for published version (APA):
Jensen, M. D., Siersma, V. D., Rasmussen, J. F., & Brodersen, J. (2020). Direct and indirect healthcare costs of lung cancer CT screening in Denmark: a registry study . *B M J Open*, *10*(1), [e031768].
<https://doi.org/10.1136/bmjopen-2019-031768>

BMJ Open Direct and indirect healthcare costs of lung cancer CT screening in Denmark: a registry study

Manja Dahl Jensen ¹, Volkert Siersma,¹ Jakob Fraes Rasmussen,¹ John Brodersen^{1,2}

To cite: Jensen MD, Siersma V, Rasmussen JF, *et al.* Direct and indirect healthcare costs of lung cancer CT screening in Denmark: a registry study. *BMJ Open* 2020;**10**:e031768. doi:10.1136/bmjopen-2019-031768

► Prepublication history for this paper is available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2019-031768>).

Received 17 May 2019
Revised 24 December 2019
Accepted 02 January 2020



© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

¹The Research Unit for General Practice and Section of General Practice, Department of Public Health, University of Copenhagen, Copenhagen, Denmark

²Primary Healthcare Research Unit, Zealand Region, Copenhagen, Denmark

Correspondence to Manja Dahl Jensen; madj@sund.ku.dk

ABSTRACT

Introduction A study based on the Danish Randomised Controlled Lung Cancer Screening Trial (DLCST) calculated the healthcare costs of lung cancer screening by comparing costs in an intervention group with a control group. Participants in both groups, however, experienced significantly increased negative psychosocial consequences after randomisation. Substantial participation bias has also been documented: The DLCST participants reported fewer negative psychosocial aspects and experienced better living conditions compared with the random sample.

Objective To comprehensively analyse the costs of lung cancer CT screening and to determine whether invitations to mass screening alter the utilisation of the healthcare system resulting in indirect costs. Healthcare utilisation and costs are analysed in the primary care sector (general practitioner psychologists, physiotherapists, other specialists, drugs) and the secondary care sector (emergency room contacts, outpatient visits, hospitalisation days, surgical procedures and non-surgical procedures).

Design To account for bias in the original trial, the costs and utilisation of healthcare by participants in DLCST were compared with a new reference group, selected in the period from randomisation (2004–2006) until 2014.

Setting Four Danish national registers.

Participants DLCST included 4104 current or former heavy smokers, randomly assigned to the CT group or the control group. The new reference group comprised a random sample of 535 current or former heavy smokers in the general Danish population who were never invited to participate in a cancer screening test.

Main outcome measures Total healthcare costs including costs and utilisation of healthcare in both the primary and the secondary care sector.

Results Compared with the reference group, the participants in both the CT group (offered annual CT screening, lung function test and smoking counselling) and the control group (offered annual lung function test and smoking counselling) had significantly increased total healthcare costs, calculated at 60% and 48% respectively. The increase in costs was caused by increased use of healthcare in both the primary and the secondary sectors.

Conclusion CT screening leads to 60% increased total healthcare costs. Such increase would raise the expected annual healthcare cost per participant from EUR 2348 to EUR 3756. Cost analysis that only includes costs directly

Strength and limitations of this study

- Our analysis included costs from both the primary sector and the secondary sector.
- Our analysis accounted for the possible bias in the original study resulting from increased negative psychosocial consequences for participants in both the CT group and the control group after randomisation.
- The risk of contamination, defined as screening in the control group (or reference group), was most likely low.
- This study is not a randomised controlled trial, but we have adjusted the analysis for a number of possible confounders, in particular the socioeconomic variables.
- The following costs have not been accounted for: costs in relation to days off work for CT screening and follow-up, costs of psychiatric hospitalisation, costs of medication bought without a prescription, costs of retirement and sick days and the influence of a cancer diagnosis on the insurance conditions of participants.

related to the CT scan and follow-up procedures most likely underestimates total costs. Our data show that the increased costs are not limited to the secondary sector.

Trial registration number NCT00496977.

INTRODUCTION

There are strong incentives to screen for lung cancer: first, it is the primary cause of cancer-related deaths in the world^{1,2} and the aim of screening is to lower mortality by detecting and treating the cancer earlier. Second, most people diagnosed with lung cancer (80% in the USA) are former smokers³ who cannot benefit from primary prevention as they have already stopped smoking.

Lung cancer CT screening

In the USA, the National Lung Screening Trial (NLST) showed a 16% relative risk (RR) reduction in lung-cancer-specific mortality⁴ and 6.7% RR reduction in all-cause mortality after 6.5 years of follow-up.⁵ Based on these

results, several American medical organisations recommend lung cancer screening,⁶ including the US Preventive Service Task Force (USPSTF)⁷ and The American Cancer Society.⁸ They recommend lung cancer CT screening for high-risk individuals: current smokers aged 55–74 (80 for USPSTF) with a smoking history of at least 30 pack-years; or, former smokers aged 55–74 (80 for USPSTF) who have stopped smoking within the past 15 years. As a consequence of the NLST study, lung cancer screening has now been implemented in the USA.

The European Society of Radiology (ESR) and the European Respiratory Society (ERS) also recommend lung cancer screening for high-risk individuals.⁶ In Europe, there have been seven randomised controlled trials (RCTs), including the Danish Lung Cancer Screening Trial (DLCST).³ So far, the European studies that have published their final mortality results were unable to find a statistically significant mortality reduction from screening.^{9,10} There could be a number of reasons for this finding: it could be due to lack of effect; a short follow-up period; the inclusion of more people with a lower risk (fewer pack-years of smoking) in the European trials and/or that the studies are underpowered.^{3,10–13}

Systematic reviews have found significant heterogeneity in methodology and results of economic evaluations of lung cancer screening.^{14,15} Several researchers have analysed the cost-effectiveness of CT screening based on the NLST. One study estimated that the cost of preventing one lung cancer death was US\$240 000.¹⁶ A second study revealed that screening with low-dose CT would cost US\$81 000 per quality-adjusted life year (QALY) gained.¹⁷ Other studies found that the cost per life-year saved would be below US\$19 000¹⁸ and that the average annual cost of lung cancer screening per person screened would be US\$241.¹⁹ A study assessing the cost-effectiveness of CT screening within the Canadian healthcare system, estimated a cost-effectiveness of CAD 52 000 per QALY²⁰ and another that high-risk screening would cost CAD 20 724 per QALI gained.

Using the outcomes from the NLST and cost and survival data in Australia estimated cost-effectiveness at AUD 233 000 per QALY gained.²¹

Two recent systematic reviews of cost-effectiveness analyses of Lung Cancer Screening concluded that it is still unclear whether or not low dose CT screening is cost effective.^{14,15} Several things can influence cost-effectiveness estimates among other: overdiagnosis, lead-time bias, the at-risk population, the characteristics of a smoking cessation programme and incidental findings.^{14,15} Only one study included incidental findings.^{15,17}

The Danish Lung Cancer Screening Trial (DLCST)

The DLCST included 4104 current or former heavy smokers and participants were randomly assigned to the CT group or the control group. All participants took part in annual lung function testing and smoking counselling. The participants in the CT group also received an annual CT scan.¹² Based on the DLCST, Rasmussen

*et al*²² investigated the direct and indirect costs of lung cancer screening. This study documented a statistically significant difference in total healthcare costs between the CT group and the control group when the costs of the screening programme were included. When these costs were excluded, there was no statistically significant difference between the two groups. According to the authors,^{22,23} three conditions might have influenced their cost estimates resulting in either an underestimation or an overestimation.

First, the participants in both the CT group *and* the control group experienced more negative psychosocial consequences after randomisation compared with baseline (before randomisation). This overall increased concern may have resulted in increased use of healthcare in both groups. In that case calculating the difference between costs in the two groups would then lead to underestimation of the real costs.

Second, lost income and productivity, early retirement, sick leave and use of medicines were not included in the analysis. Third, a further study on participation bias²⁴ showed that participants in DLCST differed significantly from a representative sample of heavy smokers in the general population. The DLCST participants reported fewer negative psychosocial aspects and experienced better living conditions compared with the random sample. This bias could have resulted in underestimation or overestimation of healthcare costs.

The aim of this study, therefore, was to conduct a comprehensive analysis of healthcare costs in relation to lung cancer CT screening, using the work by Rasmussen *et al*²² as a starting point. We included the costs of prescription medication in the analysis. In addition, we involved a new reference group to avoid the possible impact on healthcare cost and utilisation estimates from the control group in the original trial who experienced increased concern after randomisation, and to account for the revealed participation bias among DLCST participants.

METHOD

Definitions of costs

We defined 'total costs' as the total amount paid by the Danish state for healthcare services in the primary care sector (general practitioner (GP) contacts, GP costs, psychologist costs, physiotherapist costs, other specialist costs, prescription drug costs), plus healthcare services in the secondary care sector (emergency room contacts, outpatient visits, hospitalisation days, surgical procedures and non-surgical procedures). In addition, 'total costs' included the out-of-pocket costs for individual patients related to prescription drugs as well as medical reimbursement paid by the state. The cost of prescription medication paid for by the patient was included without value-added tax. We calculated total costs with the costs of the CT scan included and also excluded. Direct costs include all costs in relation to the screening procedure: the CT scan, the staff, the follow-up procedures and the




Figure 1 Trial flow. DLCST, Danish Randomised Controlled Lung Cancer Screening Trial.

housing. Indirect costs include: unintended extra health-care use not directly related to CT screening.

Study population

DLCST participants (the CT group and the control group) were compared with a reference group that had not been invited to screening (figure 1). The present study, therefore, included participants from two cohorts:

1. DLCST took place from October 2004 to March 2010. The study design has been described in detail elsewhere.¹² Briefly, 4104 participants were included voluntarily in the trial. They had to be current or former heavy smokers (at least 20 pack-years) and aged 50–70 years. The participants were randomly assigned to either the CT group or the control group. No statistically significant differences in baseline socioeconomic characteristics or smoking habits were found between the two groups. All participants made annual visits to a screening clinic, where they completed questionnaires and received lung function tests and smoking counselling. In addition, the CT group received a CT scan. Participants with positive CT scans were referred for diagnostic workup.¹²
2. The reference group included 535 participants from the study ‘Participation bias in a randomised trial of screening for lung cancer’²⁴ who met the inclusion criteria for DLCST and belonged to the same birth cohorts as DLCST participants. As previously reported, the reference group was more representative of former

and heavy smokers in the general Danish population²⁴ compared with DLCST participants, and they differed markedly with regard to socioeconomic characteristics.

The baseline characteristics of participants in DLCST (both CT and control) and in the reference group are shown in table 1. For a more comprehensive discussion of differences in characteristics, see Hestbech *et al.*²⁴

Registries and outcomes

Denmark has a publicly financed healthcare system and all citizens have a unique identification number. Every time a person uses the healthcare system the type of contact and the cost is recorded in national registries. This was also the case for all participants of the DLCST.

There is an economic incentive for the providers to register services as their reimbursement depends on the invoice. The data for this study were extracted from these registries, namely: National Patient Registry; National Health Insurance Registry; Diagnostic Related Groups-Diagnostic Outpatient Group System Registries; Drug Registry. We chose a set of outcomes to reflect a comprehensive summary of healthcare utilisation in primary and secondary care sector (table 2).

DLCST budget

The DLCST was financed by the Ministry of Health and Prevention. A grant of EUR 2.33 million covered the expenses of 9800 CT scans, including recruitment of participants and staff salaries.²² All procedures in the

**Table 1** Participant baseline characteristics in DLCST (CT and control) and the reference group

Characteristics	N/N/N	CT group (n=2052)	Control group (n=2052)	Reference group (n=535)
Sex, n (%)				
Men	2052/2052/535	1147 (55.9)	1120 (54.6)	335 (62.6)
Women		905 (44.1)	932 (45.4)	200 (37.4)
Age (years), mean (SD)	2052/2052/535	57.3 (4.8)	57.3 (4.8)	57.0 (4.4)
SG, n (%)				
I	2041/2039/489	155 (7.6)	141 (6.9)	25 (5.1)
II		402 (19.7)	410 (20.1)	69 (14.1)
III		378 (18.5)	378 (18.5)	88 (18.0)
IV		545 (26.7)	551 (27.0)	152 (31.1)
V		265 (13.0)	282 (13.8)	110 (22.5)
Employed, SG uncertain		182 (8.9)	168 (8.2)	25 (5.1)
Outside the labour market		114 (5.6)	109 (5.4)	20 (4.1)
School education, n (%)				
7–9 years in school	2047/2047/533	698 (34.1)	715 (34.9)	241 (45.2)
10 years in school		775 (37.9)	790 (38.6)	151 (28.3)
12–13 years in school		553 (27.0)	532 (26.0)	100 (18.8)
Other		21 (1.0)	10 (0.5)	41 (7.7)
Vocational education				
None	2043/2047/531	187 (9.2)	201 (9.8)	81 (15.3)
Semiskilled worker		20 (1.0)	27 (1.3)	36 (6.8)
Vocational training		702 (34.4)	724 (35.4)	133 (25.1)
Short further education		199 (9.7)	194 (9.5)	41 (7.7)
Middle further education		506 (24.8)	539 (26.3)	110 (20.7)
Long further education		264 (12.9)	225 (11.0)	49 (9.2)
Other		165 (8.1)	137 (6.7)	81 (15.3)
Employment status, n (%)				
Employed	2043/2045/533	1366 (66.9)	1324 (64.7)	236 (44.3)
Studying		9 (0.4)	12 (0.6)	0
Job seeking		113 (5.5)	104 (5.1)	17 (3.2)
Retired		555 (27.2)	605 (29.6)	280 (52.5)
Region of residence, n (%)				
Capital region	2037/2044/535	1644 (80.7)	1653 (80.9)	163 (30.5)
Region Zealand		353 (17.3)	349 (17.1)	72 (13.5)
Region of Southern Denmark		29 (1.4)	28 (1.4)	129 (24.1)
Region of Central Denmark		8 (0.4)	11 (0.5)	113 (21.1)
Region of Northern Denmark		3 (0.2)	3 (0.2)	58 (10.8)
Living alone, n (%)				
No	2039/2034/533	1457 (71.5)	1453 (71.4)	415 (77.9)
Yes		582 (28.5)	581 (28.6)	118 (22.1)
Smoking status, n (%)				
Current smoker	2050/2051/534	1544 (75.3)	1579 (77.0)	276 (51.7)
Former smoker		506 (24.7)	472 (23.0)	258 (48.3)
Smoking history (pack years), mean (SD)	2051/2048/535	36.4 (13.4)	35.9 (13.4)	36.9 (17.7)

DLCST, Danish Randomised Controlled Lung Cancer Screening Trial; SD, Standard Deviation; SG, social group.

Table 2 Overview of outcomes and the registries used to extract data

Outcomes:	Registers				Description of outcome
	NPR	NHI	DRG-DAGS	DR	
Primary care					
GP contacts		x			Number of contacts with GPs (ordinary consultations, home visits, telephone and email consultations)
GP costs		x			Healthcare costs of GPs
Other specialist MD costs		x			Healthcare costs of specialised medical doctors in primary care (excl. GPs and dentists)
Psychologist costs		x			Healthcare costs of psychologists in primary care
Physiotherapist costs		x			Healthcare costs of physiotherapists in primary care
Prescription drug costs				x	Costs of prescription drugs
Secondary care					
Hospitalisation days	x				Days in hospital, not as outpatient
Outpatient visits	x				Number of visits to outpatient clinic
Emergency room contacts	x				Number of out-of-hours contacts with GPs and all contacts with emergency rooms.
Surgical procedures	x				Number of surgical procedures in hospital
Non-surgical procedures	x				Number of non-surgical procedures and techniques in hospital.
Total costs		x	x		Total healthcare costs in primary and secondary sectors excluding costs in the psychiatric secondary sector.
		Plus the price of CT scans in the study setting: EUR 238/CT scan including recruitment of participants and staff salaries.			

DR, Drug Registry; DRG-DAGS, Diagnostic Related Groups-Diagnostic Outpatient Group System Registries; GP, general practitioner; MD, medical doctor; NHI, National Health Insurance Registry; NPR, National Patient Registry.

follow-up of participants with abnormal findings in their CT scans were billed to the Danish healthcare system and thus recorded in the public registries.²² This includes costs of any incidental findings.

Outcomes

Outcomes are selected healthcare costs over the period from date of randomisation (2004/2006) until the end of 2014, death or migration (figure 2). Outcomes were annualised into outcome per year to adjust for different observation times. Participants with an observation time <12 months were excluded to avoid inflation of healthcare costs when annualising the outcomes. To make the reference group comparable to the two randomisation groups of the DLCST in this respect, a virtual randomisation date was determined by randomly selecting a date from among DLCST participants whose date of birth was in the same quarter as the participant in the reference group. Data on healthcare utilisation in the 10-year period before DLCST was used for adjustments.

Statistical analysis

Outcomes that are rarely used by the population include many zero observations (eg, surgical procedures).

Consequently, it is more appropriate to analyse the risk of having, for example, a surgical procedure at all in the observation period, that is, the incidence of use. Outcomes that are frequently used do not have many zero observations (eg, total costs). For these outcomes, it is more relevant to analyse the quantity of use. A multi-variable analysis of the outcomes, therefore, followed a two-part model²⁵ where separately the yearly incidence and the yearly use of the various outcomes in the two DLCST groups were compared with the reference group:

1. In part one, we analysed the incidence of use of selected healthcare services, or costs, in the observation period. This incidence was analysed in a Poisson regression approach so the regression parameters were equivalent to the logarithm of the RR of ever using the service;²⁶ the logarithm of the observation period was used as an offset so that yearly incidences are compared.
2. In part two, we analysed the quantity of healthcare costs or services. Only the participants who used the services or had costs >0 were included in this part, and the quantity of use was analysed in a generalised linear model using a Gamma distribution and a logarithmic link function. The parameters from this model were interpreted as the

Figure 2: Timeline and data collection




Figure 2 Timeline and data collection. DLCST, Danish Randomised Controlled Lung Cancer Screening Trial.

logarithm of a multiplicative factor of how much more the service was used (or how much more cost was incurred) in the CT group or the control group compared with the use/cost in the reference group; the logarithm of the observation period was used as an offset so that annualised costs are compared.

Since the groups were not randomised, it was necessary to address the differences in baseline characteristics between the DLCST participants and the reference group (table 1). The following possible confounders were accounted for using multivariable regression models for the above-described two parts: sex, age, (squared), employment, living alone, socioeconomic group, smoking status, pack years, pack years squared, region of residence, Charlson's comorbidity index and healthcare use in the 10 years prior to randomisation.

A combined multiplicative effect of being in the CT group or in the control group compared with being in the reference group was calculated by multiplying the RR from the incidence part of the model and the factor from the quantity part. This is referred to as the *cumulative effect*.

Statistical significance was adjusted for multiple testing by controlling the false discovery rate at 5% using the method of Benjamini-Hochberg. The level of statistical significance was then asserted at a level of 0.0202.

Total costs that might have been *expected* in the reference group (if the reference group had been invited for screening) were calculated by multiplying the mean total costs in the reference group with the cumulative effect in the CT and control group calculated in the two-part model.

We used SAS V.9.4 for the statistical analysis (SAS Institute, Cary, North Carolina, USA).

Patient involvement

In this study, patients were not directly involved in setting the research question, the outcome measures or in the design or implementation of the study. The research question and design, however, were informed by how participants experienced lung cancer CT screening as revealed in a qualitative study²² (ie, how they were psychosocially affected). This study assessed the burden of the intervention on participants (allocation to the CT screening group or the control group).

Ethics

All participants signed an informed consent form. Both the DLCST (number 2005-53-1083) and this project (number 2014-41-2877) have been approved by the Danish Data Protection Agency.

RESULTS

The baseline characteristics of the three groups are shown in table 1. All of the socioeconomic characteristics are possible confounders because of comprehensive differences, and we have made adjustments accordingly.

Costs are presented in Euro (EUR), converted from Danish Kroner (DKK) using the 26 January 2016 spot rate DKK 746.22=EUR 100).

Total costs including the costs of a lung CT screening programme

Lung CT screening increased the mean total annual healthcare costs by 60% (table 3, figure 3). Lung function tests and smoking counselling alone (as applied to the

Table 3 RR (incidence) and factor (quantity) of healthcare use in the DLCST groups compared with the reference group

Total costs	Groups	RR	RR lower 95% CI	RR upper 95% CI	RR p value	Factor (F)	F lower 95% CI	F upper 95% CI	Factor p value	Cumulative effect
Total costs excl. direct cost of CT-screening programme	CONT	1.008	0.994	1.022	0.284	1.468	1.325	1.627	0.000*	1.479
	CT	1.013	0.999	1.027	0.068	1.501	1.354	1.663	0.000*	1.520
	REF	1.000	1.000	1.000	–	1.000	1.000	1.000	–	1.000
Total costs incl. cost of CT-screening programme	CONT	1.008	0.994	1.022	0.286	1.471	1.334	1.622	0.000*	1.483
	CT	1.012	0.999	1.026	0.073	1.585	1.437	1.747	0.000*	1.604
	REF	1.000	1.000	1.000	–	1.000	1.000	1.000	–	1.000
Secondary sector										
Hospitalisation days	CONT	1.137	1.000	1.293	0.050	0.989	0.856	1.144	0.884	1.125
	CT	1.137	0.999	1.295	0.051	1.056	0.914	1.221	0.457	1.202
	REF	1.000	1.000	1.000	–	1.000	1.000	1.000	–	1.000
Outpatient visits	CONT	1.085	1.032	1.142	0.002*	1.012	0.930	1.102	0.777	1.099
	CT	1.065	1.012	1.121	0.016*	1.046	0.961	1.139	0.301	1.114
	REF	1.000	1.000	1.000	–	1.000	1.000	1.000	–	1.000
Emergency room contacts	CONT	1.144	1.057	1.239	0.001*	1.102	1.020	1.192	0.014*	1.261
	CT	1.144	1.057	1.239	0.001*	1.110	1.026	1.200	0.009*	1.270
	REF	1.000	1.000	1.000	–	1.000	1.000	1.000	–	1.000
Surgical procedures	CONT	1.065	0.975	1.163	0.163	1.024	1.098	1.098	0.511	1.090
	CT	1.063	0.973	1.162	0.178	1.034	1.109	1.109	0.355	1.099
	REF	1.000	1.000	1.000	–	1.000	1.000	1.000	–	1.000
Non-surgical procedures	CONT	1.028	0.992	1.034	0.134	0.966	0.901	1.034	0.318	0.992
	CT	1.020	0.984	1.028	0.278	0.96	0.896	1.028	0.244	0.979
	REF	1.000	1.000	–	–	1.000	1.000	1.000	–	1.000
Primary sector										
GP contacts	CONT	1.018	1.002	1.035	0.024	1.041	1.000	1.084	0.053	1.060
	CT	1.025	1.010	1.041	0.002*	1.035	0.994	1.078	0.094	1.062
	REF	1.000	1.000	1.000	–	1.000	1.000	1.000	–	1.000
GP costs	CONT	1.021	1.005	1.037	0.009*	1.052	1.013	1.093	0.009*	1.074
	CT	1.028	1.012	1.044	0.006*	1.049	1.010	1.090	0.013*	1.078
	REF	1.000	1.000	1.000	–	1.000	1.000	1.000	–	1.000
Other specialist MD costs	CONT	1.105	1.056	1.156	0.000*	1.075	1.011	1.143	0.022	1.188
	REF	1.000	1.000	1.000	–	1.000	1.000	1.000	–	1.000

Continued



Table 3 Continued

Total costs	Groups	RR	RR lower 95% CI	RR upper 95% CI	RR p value	Factor (F)	F lower 95% CI	F upper 95% CI	Factor p value	Cumulative effect
Total costs	CT	1.094	1.045	1.145	0.000*	1.072	1.008	1.141	0.027	1.173
	REF	1.000	1.000	1.000	-	1.000	1.000	1.000	-	1.000
Psychologist costs	CONT	1.073	0.667	1.727	0.772	0.987	0.795	1.226	0.906	1.059
	CT	0.972	0.588	1.607	0.912	1.053	0.848	1.309	0.640	1.024
Physiotherapist costs	REF	1.000	1.000	1.000	-	1.000	1.000	1.000	-	1.000
	CONT	1.163	1.036	0.011*	1.107	1.107	0.968	1.266	0.139	1.287
Prescription drug costs	CT	1.170	1.042	0.008*	1.032	1.032	0.902	1.181	0.642	1.208
	REF	1.000	1.000	-	1.000	1.000	1.000	1.000	-	1.000
Prescription drug costs	CONT	1.036	1.014	0.001*	1.063	1.063	0.967	1.167	0.205	1.101
	CT	1.041	1.019	0.000*	1.044	1.044	0.950	1.147	0.371	1.087
Prescription drug costs	REF	1.000	1.000	-	1.000	1.000	1.000	1.000	-	1.000

Cumulative effect=relative risk \times factor. After adjustments for multiple testing using the method of Benjamini-Hochberg the level of statistical significance was asserted at 0.0202. CONT, control group from DLCST; CT, CT group from DLCST; DLCST, Danish Randomised Controlled Lung Cancer Screening Trial; GP, general practitioner; REF, Reference group; RR, relative risk.

control group) increased the mean total annual healthcare costs by 48% (table 3, figure 3, cumulative effect 1.48).

The participants in the reference group (unexposed to any of the trial interventions) had a mean total annual healthcare cost of EUR 2348. If this reference group had been exposed to CT screening, the mean total annual healthcare costs would increase by 60%, from EUR 2348 to EUR 3756. If the reference group had been exposed to lung function tests and smoking counselling alone, the mean total annual healthcare costs would increase by 48% to EUR 3474.

Total costs excluding the direct costs of a lung CT screening programme

CT screening increased the mean total annual healthcare costs by 52% (table 3, figure 3). Lung function tests and smoking counselling alone increased the mean total annual healthcare costs by 48% (table 3, figure 3). As lung function tests and smoking counselling were part of the DLCST budget, the 52% and 48% increases in costs are attributed to altered healthcare use by participants after the invitation to attend screening.

Primary healthcare outcomes

Compared with the reference group, the participants in the CT group had significantly increased healthcare use in five out of six outcomes, and the participants in the control group in four out of six outcomes. With respect to quantity (part two of the model), only one outcome differed significantly between the CT group and the control group, respectively, compared with the reference group (table 3, figure 3).

Secondary healthcare outcomes

Compared with the reference group, the participants in both the CT group and the control group had significantly increased healthcare use in two out of five outcomes and, with respect to quantity, in one out of five outcomes (table 3, figure 3).

DISCUSSION

Lung cancer CT screening increased mean total annual healthcare costs by 60% and a substantial part of these costs, 52%, were indirect costs. Lung function tests and smoking counselling alone accounted for a 48% increase in mean costs, and only 12% (60%–48%) of the indirect costs can be attributed to more lung-cancer cases in the CT group. The remaining 48% can be partly explained by finding a drop in lung function. As the results show, however, an increased use of emergency room contacts, for example, which cannot be attributed to more chronic obstructive pulmonary disease diagnosis, indicates that other potential explanations must be explored. Our findings underline the importance of including all relevant costs, including those from the primary care sector. In addition, these findings emphasise the need for using a blinded control group that is unaware of the ongoing




Figure 3 Relative risk (incidence) and factor (quantity) of healthcare use in the DLCST groups compared with the reference group. DLCST, Danish Randomised Controlled Lung Cancer Screening Trial; GP, general practitioner.

screening trial. The unblinded control group in the DLCST was affected negatively after randomisation, which could cause a statistically non-significant difference in costs between the intervention and control groups.²²

The cost-effectiveness of CT screening has been reported by other researchers.¹⁵ Only two studies included indirect costs: one included lost wages and another included losses due to travel time associated with screening.¹⁵ If primary care sector costs had been included in the analysis, total costs would most likely have been higher, as our data show that the increased costs are not limited to the secondary care sector.

If CT screening is effective, one would expect more lung-cancer cases to be found in the CT group than in the control group, and for that reason higher healthcare utilisation in the CT group than in the control group. Incidental findings described to a varying degree²⁷ could also contribute to increased healthcare utilisation and costs in the CT group compared with the control group. Incidental findings such as coronary artery calcification and emphysema could cause less morbidity and mortality but also potentially overtreatment, complications and increased costs.¹⁵

In DLCST, a high degree of overdiagnosis has been reported (67.2%)²⁸ which would also contribute to increased costs in the CT group. Our data show, however, that both the CT group and the control group had increased healthcare utilisation. Consequently, extra healthcare use induced by the CT screening programme cannot be attributed to an increase in lung cancer cases and incidental findings alone. Both trial groups were offered annual lung function tests and smoking counselling. Therefore, a part of the extra healthcare use in both groups might stem from finding a drop in lung function.

Studies have shown that smokers who participated in lung cancer screening had a higher smoking cessation rate compared with smokers in the general population.^{29 30} Smoking counselling intervention increases the cost of a screening programme but might reduce morbidity and long-term health costs.²¹

Studies have shown that non-lung cancer outcomes such as mortality reductions or long-term improvements to quality of life for participants without lung cancer were drivers of the cost-effectiveness of lung cancer screening.^{20 31} In contrast to the mentioned findings of long-term improvements to quality of life, a study from DLCST demonstrated that the participants in the CT group and in the control group experienced more negative psychosocial consequences after randomisation compared with baseline.³² A systematic review of the psychological burden of lung cancer screening in different countries found variable results with large heterogeneity in outcome measures.³³ The questionnaire used to measure the potential psychosocial consequences of lung cancer screening in DLCST had high content validity and adequate psychometric properties, fulfilling the COSMIN criteria for valid patient-reported outcome measures.³⁴ This is in contrast to the questionnaires used in other trials.

Studies have shown that negative expectations for the future can change how a person perceives signs and symptoms in the body,^{35 36} and can, in addition, give rise to actual physical changes.^{37 38} If a person feels concerned or experiences more physiological symptoms, it would be natural to seek medical attention and thereby have a higher utilisation of healthcare. The increased negative psychosocial consequences experienced in the two groups of DLCST may have been because they were



reminded of being at risk of serious illness. In short, the need for further tests or treatment for a drop in lung function, appointments to address anxiety-related issues and seeking immediate medical advice for things that might have resolved without any medical intervention are all possible explanations for increased healthcare costs and utilisation.

The present study has limitations. First, it was not an RCT, but we adjusted the analysis for a number of possible confounders. Second, the following costs have not been accounted for: costs in relation to days off work due to CT screening and follow-up; costs of psychiatric hospitalisation; costs of medication bought without prescription; costs of retirement and of sick days, and the fact that a cancer diagnosis could influence the insurance conditions of the participants. The latter is especially important when the high rate of overdiagnosis in DLCST is taken into account. Third, implementing lung cancer screening could affect smokers who are not the target of the screening programme, for example, smokers with a smoking history <20 pack-years; smokers aged <50, >70 or smokers with body weight >130 kg or FEV1 <30%. Costs are underestimated if smokers who are *not* invited for screening are psychosocially affected, as seen in the DLCST control group, assuming that some of the extra costs were caused by a change in illness perception. A study on mammography screening concluded that the absence of an invitation to breast cancer screening had a negative psychosocial impact.³⁹ Fourth, the cost of a CT scan in a screening setting (EUR 238/scan) was higher than the cost of a CT scan in a diagnostic setting (EUR 186).²² If screening is implemented and becomes routine, the cost of a scan will probably drop and the same goes for the total costs. Fifth, as seen in [figure 2](#), data collection extended beyond the screening period. This means that our estimates of ‘total costs *including* the costs of the CT-screening programme’ are probably underestimated.

We are assuming that the number of missing data is insignificant due to the economic incentive to report all services provided. Denmark has a publicly financed healthcare system. When doctors and other healthcare professionals and hospitals are providing a service, they must report it to the health authorities to be refunded. The reported services are registered in National registries.

It has been argued that patients are most likely to take the decision to visit their GP, and thus this decision reflects patient characteristics. Costs per user, on the other hand, are more related to the characteristics of the healthcare system.²⁵ Our results on ‘total costs’ might not be generalisable to other countries because of presumed differences between healthcare systems. Healthcare utilisation figures and the percentage increase in ‘total costs’ induced by the screening programme might be generalisable.

The risk of contamination, defined as screening in the control group (or reference group), was most likely low.⁴⁰

Future lung cancer screening trials should, where possible, be designed with a blinded control group, that does not take part in lung function testing or visits

to a screening clinic AND is unaware that a screening programme is ongoing. In addition, future cost analyses should also include indirect costs.

CONCLUSION

CT screening for lung cancer increased mean total annual healthcare costs by 60% including the costs of the CT screening programme. This corresponds to an increase in the total annual healthcare costs per participant from EUR 2348 to EUR 3756. The increased costs were the result of increased use of healthcare in the primary as well as in the secondary sector.

Acknowledgements Thanks to all the participants who volunteered in the study. Thanks to data manager Willy Karlsund for generating the database and thanks to the other members of the DLCST steering committee: Jesper Holst Petersen, Asger Dirksen, Karen Skjoldstrup Bach, Paul Frost Clementsen, Martin Døssing, Hanne Hansen, Klaus Fuglsang Kofoed, Klaus Richter Larsen, Jann Mortensen, Niels Seersholm, Birgit Guldhammer Skov, Hanne Thorsen, Philip Tønnesen, Haseem Ashraf and Zaigham Saghir.

Contributors The study was devised by JFR, VS and JB. Data collection was done by MDJ and JFR. VS did the analysis. MDJ drafted the manuscript. VS and JB contributed to revisions of the manuscript and approved the final version. All authors had full access to all of the data in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis.

Funding The DLCST were funded by the Danish Ministry of Health and Prevention (grant number 0900814). MDJ was funded by PLU fonden (grant number R406-A28178-B22773).

Disclaimer The funders had no role in study design, data collection, analysis, interpretation, writing process or the decision to submit the article.

Competing interests All authors have completed the ICMJE uniform disclosure form at ‘http://www.icmje.org/coi_disclosure.pdf’.

Patient consent for publication Not required.

Ethics approval The DLCST was approved by the Danish Scientific Ethical Committee, number KA-02045.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data may be obtained from a third party and are not publicly available. No additional data available. Data sharing is possible only if approved by the Danish data protection agency because participants may be identifiable in the dataset. On request, we will help applying for this approval. In the long term, when all data have been processed and anonymised, data will be accessible to the public.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iD

Manja Dahl Jensen <http://orcid.org/0000-0002-2804-6487>

REFERENCES

- Ott JJ, Ullrich A, Mascarenhas M, *et al*. Global cancer incidence and mortality caused by behavior and infection. *J Public Health* 2011;33:223–33.
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. *CA Cancer J Clin* 2015;65:5–29.
- Field JK, van Klaveren R, Pedersen JH, *et al*. European randomized lung cancer screening trials: post NLST. *J Surg Oncol* 2013;108:280–6.

- 4 Pinsky PF, Church TR, Izmirlan G, *et al.* The National lung screening trial: results stratified by demographics, smoking history, and lung cancer histology. *Cancer* 2013;119:3976–83.
- 5 Aberle DR, Adams AM, Berg CD, *et al.* Reduced lung-cancer mortality with low-dose computed tomographic screening. *N Engl J Med* 2011;365:395–409.
- 6 Kauczor H-U, Bonomo L, Gaga M, *et al.* ESR/ERS white paper on lung cancer screening. *Eur Respir J* 2015;46:28–39.
- 7 U.S. Preventive Services Task Force. Lung cancer: screening. Available: <https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/lung-cancer-screening>
- 8 American Cancer Society. Lung cancer screening guidelines. Available: <http://www.cancer.org/healthy/informationforhealthcareprofessionals/acsguidelines/lungcancerscreeningguidelines/index>
- 9 Manser R, Lethaby A, Irving LB, *et al.* Screening for lung cancer. *Cochrane Database Syst Rev* 2013;160.
- 10 Han D, Heuvelmans MA, Vliegthart R, *et al.* An update on the European lung cancer screening trials and comparison of lung cancer screening recommendations in Europe. *J Thorac Imaging* 2019;34:65–71.
- 11 Wille MMW, Dirksen A, Ashraf H, *et al.* Results of the randomized Danish lung cancer screening trial with focus on high-risk profiling. *Am J Respir Crit Care Med* 2016;193:542–51.
- 12 Pedersen JH, Ashraf H, Dirksen A, *et al.* The Danish randomized lung cancer CT screening trial--overall design and results of the prevalence round. *J Thorac Oncol* 2009;4:608–14.
- 13 Coureau G, Salmi LR, Etard C, *et al.* Low-dose computed tomography screening for lung cancer in populations highly exposed to tobacco: A systematic methodological appraisal of published randomised controlled trials. *Eur J Cancer* 2016;61:146–56.
- 14 Snowsill T, Yang H, Griffin E, *et al.* Low-dose computed tomography for lung cancer screening in high-risk populations: a systematic review and economic evaluation. In: *Health technology assessment, no. 22.69*. Southampton, UK: NIHR Journals Library, 2018: 22. 1–276.
- 15 Raymakers AJN, Mayo J, Lam S, *et al.* Cost-Effectiveness analyses of lung cancer screening strategies using low-dose computed tomography: a systematic review. *Appl Health Econ Health Policy* 2016;14:409–18.
- 16 Goulart BHL, Bensink ME, Mummy DG, *et al.* Lung cancer screening with low-dose computed tomography: costs, National expenditures, and cost-effectiveness. *J Natl Compr Canc Netw* 2012;10:267–75.
- 17 Black WC, Gareen IF, Soneji SS, *et al.* Cost-Effectiveness of CT screening in the National lung screening trial. *N Engl J Med* 2014;371:1793–802.
- 18 Pyenson BS, Sander MS, Jiang Y, *et al.* An actuarial analysis shows that offering lung cancer screening as an insurance benefit would save lives at relatively low cost. *Health Aff* 2012;31:770–9.
- 19 Pyenson BS, Henschke CI, Yankelevitz DF, *et al.* Offering lung cancer screening to high-risk Medicare beneficiaries saves lives and is cost-effective: an actuarial analysis. *Am Health Drug Benefits* 2014;7:272–82.
- 20 Goffin JR, Flanagan WM, Miller AB, *et al.* Cost-Effectiveness of lung cancer screening in Canada. *JAMA Oncol* 2015;1:807–13.
- 21 Wade S, Weber M, Caruana M, *et al.* Estimating the cost-effectiveness of lung cancer screening with low-dose computed tomography for high-risk smokers in Australia. *J Thorac Oncol* 2018;13:1094–105.
- 22 Rasmussen JF, Siersma V, Pedersen JH, *et al.* Healthcare costs in the Danish randomised controlled lung cancer CT-screening trial: a registry study. *Lung Cancer* 2014;83:347–55.
- 23 Rasmussen JF. *Psychosocial consequences and healthcare costs in lung cancer CT screening: faculty of health and medical sciences University of Copenhagen PHD thesis Jakob F. Rasmussen psychosocial consequences and healthcare costs in lung cancer CT screening this thesis has been submitted to the graduate school at the faculty of health and medical sciences.* University of Copenhagen, 2014.
- 24 Hestbech MS, Siersma V, Dirksen A, *et al.* Participation bias in a randomised trial of screening for lung cancer. *Lung Cancer* 2011;73:325–31.
- 25 Diehr P, Yanez D, Ash A, *et al.* Methods for analyzing health care utilization and costs. *Annu Rev Public Health* 1999;20:125–44.
- 26 Zou G. A modified poisson regression approach to prospective studies with binary data. *Am J Epidemiol* 2004;159:702–6.
- 27 Tsai EB, Chiles C, Carter BW, *et al.* Incidental findings on lung cancer screening: significance and management. *Semin Ultrasound CT MR* 2018;39:273–81.
- 28 Heleno B, Siersma V, Brodersen J. Estimation of overdiagnosis of lung cancer in low-dose computed tomography screening: a secondary analysis of the Danish lung cancer screening trial. *JAMA Intern Med* 2018;178:1420–2.
- 29 Tammemägi MC, Berg CD, Riley TL, *et al.* Impact of lung cancer screening results on smoking cessation. *J Natl Cancer Inst* 2014;106:dju084.
- 30 Gomez MM, LoBiondo-Wood G. Lung cancer screening with low-dose CT: its effect on smoking behavior. *J Adv Pract Oncol* 2013;4:405–14.
- 31 Cressman S, Peacock SJ, Tammemägi MC, *et al.* The cost-effectiveness of high-risk lung cancer screening and drivers of program efficiency. *J Thorac Oncol* 2017;12:1210–22.
- 32 Aggestrup LM, Hestbech MS, Siersma V, *et al.* Psychosocial consequences of allocation to lung cancer screening: a randomised controlled trial. *BMJ Open* 2012;2:e000663.
- 33 Wu GX, Raz DJ, Brown L, *et al.* Psychological burden associated with lung cancer screening: a systematic review. *Clin Lung Cancer* 2016;17:315–24.
- 34 Mokkink LB, de Vet HCW, Prinsen CAC, *et al.* COSMIN risk of bias checklist for systematic reviews of patient-reported outcome measures. *Qual Life Res* 2018;27:1171–9.
- 35 Reventlow SD, Hvas L, Malterud K. Making the invisible body visible. bone scans, osteoporosis and women's bodily experiences. *Soc Sci Med* 2006;62:2720–31.
- 36 Hvas L, Reventlow S, Jensen HL, *et al.* Awareness of risk of osteoporosis may cause uncertainty and worry in menopausal women. *Scand J Public Health* 2005;33:203–7.
- 37 Reeves RR, Ladner ME, Hart RH, *et al.* Nocebo effects with antidepressant clinical drug trial placebos. *Gen Hosp Psychiatry* 2007;29:275–7.
- 38 Johansen O, Brox J, Flaten MA. Placebo and nocebo responses, cortisol, and circulating beta-endorphin. *Psychosom Med* 2003;65:786–90.
- 39 Osterø J, Siersma V, Brodersen J. Breast cancer screening implementation and reassurance. *Eur J Public Health* 2014;24:258–63.
- 40 Saghir Z, Ashraf H, Dirksen A, *et al.* Contamination during 4 years of annual CT screening in the Danish lung cancer screening trial (DLCST). *Lung Cancer* 2011;71:323–7.